Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890

Article summary

Adagene Inc. has initiated dosing for the first patient in a Phase 1 clinical trial evaluating the combination of its antibody muzastotug with Incyte's bispecific antibody INCA33890 for treating microsatellite stable colorectal cancer.